PDS Biotechnology Corporation

Contributing Author

Recent Articles by PDS Biotechnology Corporation

Sep-22	PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology PDSB +8.09% GlobeNewswire
Sep-14	PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors PDSB +35.33% GlobeNewswire
Sep-08	PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PDSB +36.36% GlobeNewswire
Aug-13	PDS Biotech Reports Second Quarter 2026 Financial Results PDSB GlobeNewswire
Aug-11	PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 PDSB -64.87% GlobeNewswire
May-13	PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update PDSB +20.91% GlobeNewswire
May-06	PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results PDSB GlobeNewswire
Apr-15	PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial PDSB +28.30% GlobeNewswire
Mar-30	PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement PDSB GlobeNewswire
Mar-24	PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results PDSB PDSB +15.38% GlobeNewswire
Feb-20	PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval PDSB GlobeNewswire
Jan-28	PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI PDSB GlobeNewswire
Jan-22	PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 PDSB GlobeNewswire
Jan-09	PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint PDSB +7.72% GlobeNewswire
Dec-09	PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan PDSB +18.00% GlobeNewswire
Dec-02	PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ("FDA") PDSB +6.95% GlobeNewswire
Nov-13	PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update PDSB -12.33% GlobeNewswire
Nov-11	PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering PDSB +8.75% PDSB -9.08% GlobeNewswire
Nov-10	PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 PDSB +7.04% GlobeNewswire
Nov-06	PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results PDSB GlobeNewswire
Oct-30	New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting PDSB -5.94% GlobeNewswire
Oct-29	PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer PDSB +8.25% GlobeNewswire
Sep-18	PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population PDSB GlobeNewswire
Sep-02	PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PDSB GlobeNewswire
Aug-25	PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer PDSB +9.24% GlobeNewswire
Aug-13	PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update PDSB -5.69% GlobeNewswire
Aug-06	PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results PDSB GlobeNewswire
Jul-10	PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results PDSB GlobeNewswire
Jun-09	PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC PDSB GlobeNewswire
Jun-02	PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-22	PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting PDSB GlobeNewswire
May-20	PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase PDSB +11.64% GlobeNewswire
May-14	PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update PDSB GlobeNewswire
May-09	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDSB PDSB +7.50% GlobeNewswire
May-08	PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting PDSB +5.17% GlobeNewswire
May-07	PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results PDSB GlobeNewswire

PDS Biotechnology Corporation

Recent Articles by PDS Biotechnology Corporation

Upgrade your Finviz experience